MedTrace Logo

AGN-199201 for the Treatment of Erythema With Rosacea

NCT01735201 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 357

Last updated 2019-11-18

Study results available
· View outcomes & findings →

Summary

This study will evaluate the safety and efficacy of 3 doses of AGN-199201 once and twice daily compared to vehicle for the treatment of moderate to severe facial erythema associated with rosacea.

Conditions

  • Rosacea
  • Erythema

Interventions

DRUG

AGN-199201 Dose A

AGN-199201 Dose A applied once or twice daily to the face for 28 days.

DRUG

AGN-199201 Dose B

AGN-199201 Dose B applied once or twice daily to the face for 28 days.

DRUG

AGN-199201 Dose C

AGN-199201 Dose C applied once or twice daily to the face for 28 days.

DRUG

AGN-199201 Vehicle

AGN-199201 Vehicle applied once or twice daily to the face for 28 days.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2013-05-31
Completion
2013-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01735201 on ClinicalTrials.gov